title: Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques. Effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits.
abstract: We examined whether serum cholesterol reduction alters the lesional composition of atherosclerotic plaques. To reduce serum cholesterol levels, we gave pravastatin sodium, a 3-hydroxy-3-methylglutaryl Coenzyme A reductase inhibitor, to mature Watanabe heritable hyperlipidemic rabbits, an LDL receptor-deficient animal model, for 48 weeks. Atherosclerotic lesions were immunohistochemically and conventionally stained and each lesional component area was measured by a color image analyzer. Compared with those of a placebo group, serum LDL cholesterol levels were reduced by 22% (P<.05). Data for atherosclerosis indicated a significant decrease in percent of surface lesion area (26% reduction) and in intimal thickening (30% reduction) in the abdominal aorta, as well as in coronary stenosis (29% reduction). Data for lesional composition indicated a significant decrease in the percent area of macrophage plus extracellular lipid deposits in aortic lesions (32% reduction) and coronary lesions (45% reduction). A significant increase was observed in the percent area of collagen in aortic lesions and in the percent area of smooth muscle cells in coronary lesions. The plaques seemed to become stable lesions as a result of pravastatin treatment. In conclusion, a long-term reduction of serum LDL cholesterol reduced lipid-related lesional components, in addition to suppressing the progression of established atherosclerosis.
authors.affiliation: Institute for Experimental Animals, Kobe University School of Medicine, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Shiomi
authors.forename: T
authors.initials: T
authors.lastname: Ito
authors.forename: T
authors.initials: T
authors.lastname: Tsukada
authors.forename: T
authors.initials: T
authors.lastname: Yata
authors.forename: Y
authors.initials: Y
authors.lastname: Watanabe
authors.forename: Y
authors.initials: Y
authors.lastname: Tsujita
authors.forename: M
authors.initials: M
authors.lastname: Fukami
authors.forename: J
authors.initials: J
authors.lastname: Fukushige
authors.forename: T
authors.initials: T
authors.lastname: Hosokawa
authors.forename: A
authors.initials: A
authors.lastname: Tamura
mesh_terms: D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D001011:Aorta / Q000378:metabolism / Q000473:pathology; D001161:Arteriosclerosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002784:Cholesterol / Q000097:blood*; D003331:Coronary Vessels / Q000378:metabolism / Q000473:pathology; D006949:Hyperlipidemias / Q000150:complications* / Q000188:drug therapy*; D006965:Hyperplasia / Q000188:drug therapy; D008264:Macrophages / Q000187:drug effects / Q000473:pathology; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000473:pathology; D017035:Pravastatin / Q000627:therapeutic use*; D011817:Rabbits
chemical_list: D000924:Anticholesteremic Agents; D002784:Cholesterol; D017035:Pravastatin